Vor biopharma inc.VOR.US Overview
VOR Overall Performance
VOR AI Analysis & Strategy
VOR Recent Performance
1.41%
Vor biopharma inc.
0.81%
Avg of Sector
-1.14%
S&P500
VOR PowerScanner
VOR Key Information
VOR Valuation Metrics
VOR Earnings Table
VOR Profile
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.